Burden and impact of co-morbidity and frailty in patients with RMDs in Europe: a multi-national analysis of big healthcare data


The Observational and Medical Outcomes Partnerships (OMOP) common data model (CDM) provides a framework for standardising observational health data. Multi-database studies can then be performed without a need to pool patient-level data across network sites, and with only aggregate results shared.

In this project we are mapping data from biologic registries to the OMOP CDM. This will then allow for an assessment of comorbidity in people with severe RA in Europe, and provide the basis for further collaborative projects.

Facts and Figures

Project Lead
D Prieto-Alhambra
Autonomous University of Barcelona
FOREUM research grant: € 200.000

Meet the Team

Project Lead

D Prieto-Alhambra
University of Oxford
S Khalid
University of Oxford
K Hyrich
University of Manchester
D Courvoisier
Hôpitaux Universitaires de Genève
E Nikiphorou
King's College London
A Strangfeld
German Rheumatism Research Centre
M Schäfer
German Rheumatism Research Centre
M Pombo
University Hospital Santiago de Compostela
J Závada
Charles University Prague
M Svoboda
Masaryk University Brno


To map national biologic registry data collected from different European countries to the OMOP CDM. In particular, five  biologic registries are currently being mapped to the OMOP CDM: 1) the Czech biologics register (ATTRA), 2) Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER), 3) British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), 4) German biologics register ‘Rheumatoid arthritis observation of biologic therapy’ (RABBIT), and 5) Swiss register ’Swiss Clinical Quality Management in Rheumatic Diseases’ (SCQM).

Subsequently, to summarise the available data on comorbidities across these registries.

Interim Results

A total of 64,901 individuals are included in the 5 registries being mapped to the OMOP CDM. The number of unique baseline conditions being mapped range from 17 in BSRBR-RA to 108 in RABBIT, while the number of baseline medications range from 26 in ATTRA to 802 in BSRBR-RA. Those registries which captured more comorbidities or medications generally allowed for these to be inputted as free text.

Mapping biologic registry data to the OMOP CDM is feasible. The adoption of the OMOP CDM will facilitate collaboration across registries, and allow for multi-database studies which include data from both biologic registries and other sources of health data which have been mapped to the CDM.

Patient Voice

Patient research partners are being involved as research partners throughout this project.

Project Map